Fedratinib: all 24 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
- Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)CompletedNCT05177211Phase 2Results posted
- An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedNCT03952039Phase 3Results posted
- A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 3Results posted
- Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With RuxolitinibTerminatedNCT01523171Phase 2Results posted
- Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With MyelofibrosisTerminatedNCT01437787Phase 3Results posted
- A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With MyelofibrosisCompletedNCT00724334Phase 1/2Results posted
- Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)TerminatedNCT05524857Phase 1
- Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative NeoplasmsTerminatedNCT05127174Phase 1
- A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult ParticipantsCompletedNCT05051553Phase 1
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Active, not recruitingNCT04817007Phase 1/2
- A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT04702464Phase 1
- A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Active, not recruitingNCT04446650Phase 1/2
- Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and MetforminCompletedNCT04231435Phase 1
- Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT03983239Phase 1
- A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic ImpairmentCompletedNCT03983161Phase 1
- Effect of SAR302503 on ECG Activity in Patients With Solid TumorsCompletedNCT01836705Phase 1
- Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal ImpairmentCompletedNCT01763190Phase 1
- Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic ImpairmentCompletedNCT01762462Phase 1
- Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 2
- Drug Interaction Study of SAR302503 in Patients With Solid TumorCompletedNCT01585623Phase 1
- Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedNCT01420783Phase 2
- Phase 2 Study of SAR302503 in Patients With MyelofibrosisCompletedNCT01420770Phase 2
- A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With MyelofibrosisCompletedNCT00631462Phase 1